0001628280-23-036755.txt : 20231103 0001628280-23-036755.hdr.sgml : 20231103 20231103163914 ACCESSION NUMBER: 0001628280-23-036755 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231101 FILED AS OF DATE: 20231103 DATE AS OF CHANGE: 20231103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Taveras Arthur CENTRAL INDEX KEY: 0001830901 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 231376980 MAIL ADDRESS: STREET 1: C/O X4 PHARMACEUTICALS, INC. STREET 2: 61 NORTH BEACON STREET, 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 wk-form4_1699043942.xml FORM 4 X0508 4 2023-11-01 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001830901 Taveras Arthur C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 0 1 0 0 Chief Scientific Officer 1 Common Stock 2023-11-01 4 S 0 67695 0.73 D 249323 D These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023. Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6841 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Adam S. Mostafa, attorney-in-fact 2023-11-03